TREM2 and diffuse large B-cell lymphoma: In patients with diffuse large B-cell-lymphoma, high expression of triggering receptor expressed on myeloid cells 2 (TREM2) on circulating MDSCs is associated with Arg1 expression, enhanced immunosuppressive activity against CD8+ T cells and poor prognosis including reduced progression-free survival (PFS) and overall survival (OS) [35].